NovoCure (NVCR) Convertible Debt (2023 - 2024)
NovoCure (NVCR) posted Convertible Debt of $556.5 million for Q2 2024, down 2.16% sequentially from $568.8 million in Q4 2023.
NovoCure (NVCR) Convertible Debt (2023 - 2024) Analysis & Trends
NovoCure has reported Convertible Debt for 2 years, with the latest figure at $556.5 million in Q2 2024.
- Quarterly Convertible Debt changed N/A year-over-year to $556.5 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $556.5 million (changed N/A YoY) and the FY2023 annual result came in at $568.8 million, changed N/A from the prior year.
- Convertible Debt declined to $556.5 million in Q2 2024 per NVCR's latest filing, from $568.8 million in the prior quarter.
- Over five years, Convertible Debt peaked at $568.8 million in Q4 2023 and troughed at $556.5 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.43 Bn | 196.83 Bn | 7.27 Bn |
| 2 | Stryker | 126.52 Bn | 123.04 Bn | 4.50 Bn |
| 3 | Medtronic | 119.07 Bn | 109.85 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.16 Bn | 73.62 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.59 Bn | 47.34 Bn | 1.35 Bn |
| 6 | Dexcom | 34.95 Bn | 33.00 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.72 Bn | 31.61 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.20 Bn | 22.88 Bn | 4.55 Bn |
| 9 | Steris | 23.16 Bn | 22.68 Bn | 684.20 Mn |
| 10 | NovoCure | 1.99 Bn | 1.55 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 556.51 Mn |
| Dec 31, 2023 | 568.82 Mn |